926 related articles for article (PubMed ID: 11847424)
1. Engineered antibodies take center stage.
Huston JS; George AJ
Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in biomolecular engineering.
Ryu DD; Nam DH
Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Protein engineering of antibodies.
Sandhu JS
Crit Rev Biotechnol; 1992; 12(5-6):437-62. PubMed ID: 1423650
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibodies and therapeutics].
Desgranges C
Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
[TBL] [Abstract][Full Text] [Related]
6. Antibody engineering--IBC's Tenth International Conference. 6-9 December 1999, La Jolla, CA, USA.
Carter P
IDrugs; 2000 Mar; 3(3):259-61. PubMed ID: 16103927
[TBL] [Abstract][Full Text] [Related]
7. Antibody humanization by framework shuffling.
Dall'Acqua WF; Damschroder MM; Zhang J; Woods RM; Widjaja L; Yu J; Wu H
Methods; 2005 May; 36(1):43-60. PubMed ID: 15848074
[TBL] [Abstract][Full Text] [Related]
8. Design of humanized antibodies: from anti-Tac to Zenapax.
Tsurushita N; Hinton PR; Kumar S
Methods; 2005 May; 36(1):69-83. PubMed ID: 15848076
[TBL] [Abstract][Full Text] [Related]
9. [Progression and direction of humanized antibody research].
Lin Y; Yan XY
Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
[TBL] [Abstract][Full Text] [Related]
10. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor.
Figini M; Martin F; Ferri R; Luison E; Ripamonti E; Zacchetti A; Mortarino M; Di Cioccio V; Maurizi G; Allegretti M; Canevari S
Cancer Immunol Immunother; 2009 Apr; 58(4):531-46. PubMed ID: 18704410
[TBL] [Abstract][Full Text] [Related]
11. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
12. Engineering antibodies for clinical applications.
Jain M; Kamal N; Batra SK
Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622
[TBL] [Abstract][Full Text] [Related]
13. Antibodies and genetically engineered related molecules: production and purification.
Roque AC; Lowe CR; Taipa MA
Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
[TBL] [Abstract][Full Text] [Related]
14. Antibody engineering and modification technologies.
Filpula D
Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
[TBL] [Abstract][Full Text] [Related]
15. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of engineered antibodies.
Hwang WY; Foote J
Methods; 2005 May; 36(1):3-10. PubMed ID: 15848070
[TBL] [Abstract][Full Text] [Related]
17. Development of humanized antibodies as cancer therapeutics.
Qu Z; Griffiths GL; Wegener WA; Chang CH; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Methods; 2005 May; 36(1):84-95. PubMed ID: 15848077
[TBL] [Abstract][Full Text] [Related]
18. Human antibodies by design.
Vaughan TJ; Osbourn JK; Tempest PR
Nat Biotechnol; 1998 Jun; 16(6):535-9. PubMed ID: 9624683
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
20. Engineered protein scaffolds as next-generation antibody therapeutics.
Gebauer M; Skerra A
Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
